Abstract GS5-06: A U.S. food and drug administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy

Harpreet Singh(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), JA Beaver(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Amy S. McKee(PAREXEL International (United States)), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Kirsten B. Goldberg(United States Food and Drug Administration), Suparna Wedam(United States Food and Drug Administration), LJ Howie(United States Food and Drug Administration), Erik Bloomquist(Center for Drug Evaluation and Research), R. Sridhara(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University)
Cancer Research
February 15, 2018
10.1158/1538-7445.sabcs17-gs5-06
Cited by 15

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
|PubMed|2001|861